McKesson Corporation (MCK) EV/EBITDA Ratio: 13.79x
Is McKesson Corporation’s EV/EBITDA ratio high or low?
McKesson Corporation's EV/EBITDA ratio of 13.79x is 11% below its 4-year average of 15.53x, around the middle of its 4-year range (9.32x–21.80x).
As of Friday, June 19, 2026. 23.94% below its 12-month average of 18.13x.
MCK EV/EBITDA Ratio Chart
MCK Average EV/EBITDA Ratio Chart
MCK Current vs Average EV/EBITDA Ratio Chart
MCK EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
13.79x
EV/EBITDA RATIO AVG TTM
18.13x
EV/EBITDA RATIO AVG 3Y
16.26x
EV/EBITDA RATIO AVG 5Y
15.53x
EV/EBITDA RATIO AVG 10Y
13.77x
EV/EBITDA RATIO AVG 15Y
12.86x
EV/EBITDA RATIO AVG 20Y
11.90x
CURRENT VS TTM AVG
-23.94%
CURRENT VS 3Y AVG
-15.22%
CURRENT VS 5Y AVG
-11.18%
CURRENT VS 10Y AVG
+0.15%
CURRENT VS 15Y AVG
+7.20%
CURRENT VS 20Y AVG
+15.86%
MCK Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| McKesson Corporation (MCK) | $87.88B | 13.79x | 18.13x | 16.26x | 15.53x |
| Elevance Health Inc. (ELV)vs › | $84.37B | 12.09x | 10.09x | 11.31x | 12.22x |
| HCA Healthcare, Inc. (HCA)vs › | $83.23B | 8.55x | 10.19x | 9.59x | 9.11x |
| Medtronic plc (MDT)vs › | $101.86B | 13.19x | 15.59x | 15.62x | 16.86x |
| Cigna Corporation (CI)vs › | $73.88B | 8.00x | 8.33x | 9.18x | 9.49x |
| Boston Scientific Corporation (BSX)vs › | $67.35B | 13.55x | 28.58x | 32.14x | 30.99x |
| Bristol-Myers Squibb Company (BMY)vs › | $110.27B | 10.57x | 9.69x | 16.61x | 15.42x |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $62.84B | 11.39x | 12.76x | 17.15x | 14.74x |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $114.63B | 20.82x | 22.80x | 82.19x | 54.96x |
| Stryker Corporation (SYK)vs › | $119.03B | 20.89x | 30.76x | 30.61x | 30.60x |
EV/EBITDA vs. its own history
At 13.8, EV/EBITDA is in its normal range, sitting higher than 64% of its 20-year history.
20-year low
4.7
median
11.4
20-year high
83.0
McKesson Corporation EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
McKesson Corporation EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for McKesson Corporation (MCK)?
- The EV/EBITDA ratio for MCK stock is 13.79x.
- Is McKesson Corporation's EV/EBITDA ratio high or low?
- McKesson Corporation's EV/EBITDA ratio of 13.79x is 11% below its 4-year average of 15.53x, around the middle of its 4-year range (9.32x–21.80x).
- What is the TTM average EV/EBITDA ratio for McKesson Corporation (MCK)?
- The TTM average EV/EBITDA ratio for MCK stock is 18.13x.
- What is the 3Y average EV/EBITDA ratio for McKesson Corporation (MCK)?
- The 3Y average EV/EBITDA ratio for MCK stock is 16.26x.
- What is the 5Y average EV/EBITDA ratio for McKesson Corporation (MCK)?
- The 5Y average EV/EBITDA ratio for MCK stock is 15.53x.
- What is the 10Y average EV/EBITDA ratio for McKesson Corporation (MCK)?
- The 10Y average EV/EBITDA ratio for MCK stock is 13.77x.
- What is the 15Y average EV/EBITDA ratio for McKesson Corporation (MCK)?
- The 15Y average EV/EBITDA ratio for MCK stock is 12.86x.
- What is the 20Y average EV/EBITDA ratio for McKesson Corporation (MCK)?
- The 20Y average EV/EBITDA ratio for MCK stock is 11.90x.
McKesson Corporation EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-18 | 13.79x |
| 2026-06-17 | 14.30x |
| 2026-06-16 | 14.40x |
| 2026-06-15 | 14.30x |
| 2026-06-12 | 14.37x |
| 2026-06-11 | 14.43x |
| 2026-06-10 | 14.48x |
| 2026-06-09 | 14.37x |
| 2026-06-08 | 14.07x |
| 2026-06-05 | 14.22x |
| 2026-06-04 | 13.90x |
| 2026-06-03 | 13.59x |
| 2026-06-02 | 13.54x |
| 2026-06-01 | 13.51x |
| 2026-05-29 | 13.64x |
| 2026-05-28 | 13.90x |
| 2026-05-27 | 13.89x |
| 2026-05-26 | 13.85x |
| 2026-05-22 | 14.06x |
| 2026-05-21 | 14.06x |
| 2026-05-20 | 13.86x |
| 2026-05-19 | 13.98x |
| 2026-05-18 | 14.23x |
| 2026-05-15 | 13.96x |
| 2026-05-14 | 13.73x |
| 2026-05-13 | 13.55x |
| 2026-05-12 | 13.51x |
| 2026-05-11 | 13.34x |
| 2026-05-08 | 13.53x |
| 2026-05-07 | 13.86x |
| 2026-05-06 | 15.10x |
| 2026-05-05 | 16.20x |
| 2026-05-04 | 16.33x |
| 2026-05-01 | 16.44x |
| 2026-04-30 | 16.47x |
| 2026-04-29 | 16.61x |
| 2026-04-28 | 16.85x |
| 2026-04-27 | 16.72x |
| 2026-04-24 | 16.71x |
| 2026-04-23 | 16.87x |
| 2026-04-22 | 16.73x |
| 2026-04-21 | 16.98x |
| 2026-04-20 | 17.30x |
| 2026-04-17 | 17.45x |
| 2026-04-16 | 17.46x |
| 2026-04-15 | 17.39x |
| 2026-04-14 | 17.38x |
| 2026-04-13 | 17.41x |
| 2026-04-10 | 17.43x |
| 2026-04-09 | 17.58x |
| 2026-04-08 | 17.54x |
| 2026-04-07 | 17.26x |
| 2026-04-06 | 17.26x |
| 2026-04-02 | 17.79x |
| 2026-04-01 | 17.56x |
| 2026-03-31 | 17.43x |
| 2026-03-30 | 17.33x |
| 2026-03-27 | 17.33x |
| 2026-03-26 | 17.39x |
| 2026-03-25 | 17.70x |
| 2026-03-24 | 17.74x |
| 2026-03-23 | 17.65x |
| 2026-03-20 | 17.82x |
| 2026-03-19 | 18.07x |
| 2026-03-18 | 18.48x |
| 2026-03-17 | 18.89x |
| 2026-03-16 | 18.92x |
| 2026-03-13 | 18.87x |
| 2026-03-12 | 18.94x |
| 2026-03-11 | 18.74x |
| 2026-03-10 | 18.64x |
| 2026-03-09 | 18.89x |
| 2026-03-06 | 18.46x |
| 2026-03-05 | 18.69x |
| 2026-03-04 | 19.59x |
| 2026-03-03 | 19.92x |
| 2026-03-02 | 19.83x |
| 2026-02-27 | 19.76x |
| 2026-02-26 | 19.51x |
| 2026-02-25 | 19.30x |
| 2026-02-24 | 19.19x |
| 2026-02-23 | 19.03x |
| 2026-02-20 | 19.00x |
| 2026-02-19 | 18.80x |
| 2026-02-18 | 18.99x |
| 2026-02-17 | 18.98x |
| 2026-02-13 | 18.75x |
| 2026-02-12 | 18.39x |
| 2026-02-11 | 19.11x |
| 2026-02-10 | 18.76x |
| 2026-02-09 | 19.28x |
| 2026-02-06 | 19.02x |
| 2026-02-05 | 19.19x |
| 2026-02-04 | 16.60x |
| 2026-02-03 | 18.38x |
| 2026-02-02 | 18.28x |
| 2026-01-30 | 17.97x |
| 2026-01-29 | 17.79x |
| 2026-01-28 | 17.87x |
| 2026-01-27 | 18.03x |
| 2026-01-26 | 17.87x |
| 2026-01-23 | 17.74x |
| 2026-01-22 | 17.68x |
| 2026-01-21 | 17.81x |
| 2026-01-20 | 17.78x |
| 2026-01-16 | 18.16x |
| 2026-01-15 | 18.23x |
| 2026-01-14 | 18.03x |
| 2026-01-13 | 17.82x |
| 2026-01-12 | 17.85x |
| 2026-01-09 | 17.66x |
| 2026-01-08 | 17.63x |
| 2026-01-07 | 17.82x |
| 2026-01-06 | 17.87x |
| 2026-01-05 | 17.84x |
| 2026-01-02 | 17.81x |
| 2025-12-31 | 17.74x |
| 2025-12-30 | 17.89x |
| 2025-12-29 | 17.95x |
| 2025-12-26 | 17.91x |
| 2025-12-24 | 17.87x |
| 2025-12-23 | 17.86x |
| 2025-12-22 | 17.71x |
| 2025-12-19 | 17.74x |
| 2025-12-18 | 17.55x |
| 2025-12-17 | 17.46x |
| 2025-12-16 | 17.53x |
| 2025-12-15 | 17.80x |
| 2025-12-12 | 17.61x |
| 2025-12-11 | 17.65x |
| 2025-12-10 | 17.60x |
| 2025-12-09 | 17.23x |
| 2025-12-08 | 17.29x |
| 2025-12-05 | 17.51x |
| 2025-12-04 | 17.62x |
| 2025-12-03 | 17.44x |
| 2025-12-02 | 17.94x |
| 2025-12-01 | 18.49x |
| 2025-11-28 | 18.99x |
| 2025-11-26 | 19.04x |
| 2025-11-25 | 19.16x |
| 2025-11-24 | 18.77x |
| 2025-11-21 | 18.68x |
| 2025-11-20 | 18.34x |
| 2025-11-19 | 18.40x |
| 2025-11-18 | 18.57x |
| 2025-11-17 | 18.46x |
| 2025-11-14 | 18.19x |
| 2025-11-13 | 18.28x |
| 2025-11-12 | 18.16x |
| 2025-11-11 | 18.49x |
| 2025-11-10 | 18.55x |
| 2025-11-07 | 18.39x |
| 2025-11-06 | 18.53x |
| 2025-11-05 | 18.24x |
| 2025-11-04 | 21.80x |
| 2025-11-03 | 21.29x |
| 2025-10-31 | 21.07x |
| 2025-10-30 | 21.41x |
| 2025-10-29 | 20.98x |
| 2025-10-28 | 20.91x |
| 2025-10-27 | 21.07x |
| 2025-10-24 | 20.84x |
| 2025-10-23 | 20.63x |
| 2025-10-22 | 20.69x |
| 2025-10-21 | 20.49x |
| 2025-10-20 | 20.50x |
| 2025-10-17 | 20.46x |
| 2025-10-16 | 20.20x |
| 2025-10-15 | 20.60x |
| 2025-10-14 | 20.36x |
| 2025-10-13 | 20.06x |
| 2025-10-10 | 19.92x |
| 2025-10-09 | 19.78x |
| 2025-10-08 | 19.73x |
| 2025-10-07 | 19.59x |
| 2025-10-06 | 19.38x |
| 2025-10-03 | 19.30x |
| 2025-10-02 | 19.80x |
| 2025-10-01 | 19.95x |
| 2025-09-30 | 20.13x |
| 2025-09-29 | 19.87x |
| 2025-09-26 | 19.84x |
| 2025-09-25 | 19.26x |
| 2025-09-24 | 19.84x |
| 2025-09-23 | 19.38x |
| 2025-09-22 | 18.31x |
| 2025-09-19 | 18.34x |
| 2025-09-18 | 18.14x |
| 2025-09-17 | 18.19x |
| 2025-09-16 | 18.22x |
| 2025-09-15 | 18.45x |
| 2025-09-12 | 18.65x |
| 2025-09-11 | 18.86x |
| 2025-09-10 | 18.53x |
| 2025-09-09 | 18.51x |
| 2025-09-08 | 18.31x |
| 2025-09-05 | 18.07x |
| 2025-09-04 | 18.17x |
| 2025-09-03 | 18.16x |
| 2025-09-02 | 18.18x |
| 2025-08-29 | 18.06x |
| 2025-08-28 | 17.92x |
| 2025-08-27 | 17.98x |
| 2025-08-26 | 17.91x |
| 2025-08-25 | 17.87x |
| 2025-08-22 | 18.12x |
| 2025-08-21 | 18.52x |
| 2025-08-20 | 18.45x |
| 2025-08-19 | 17.82x |
| 2025-08-18 | 17.68x |
| 2025-08-15 | 17.73x |
| 2025-08-14 | 17.75x |
| 2025-08-13 | 17.49x |
| 2025-08-12 | 17.39x |
| 2025-08-11 | 17.72x |
| 2025-08-08 | 17.62x |
| 2025-08-07 | 17.49x |
| 2025-08-06 | 18.47x |
| 2025-08-05 | 17.33x |
| 2025-08-04 | 17.37x |
| 2025-08-01 | 17.08x |
| 2025-07-31 | 16.95x |
| 2025-07-30 | 17.46x |
| 2025-07-29 | 17.40x |
| 2025-07-28 | 17.26x |
| 2025-07-25 | 17.39x |
| 2025-07-24 | 17.35x |
| 2025-07-23 | 17.44x |
| 2025-07-22 | 17.33x |
| 2025-07-21 | 17.38x |
| 2025-07-18 | 17.34x |
| 2025-07-17 | 17.35x |
| 2025-07-16 | 17.48x |
| 2025-07-15 | 17.37x |
| 2025-07-14 | 17.48x |
| 2025-07-11 | 17.34x |
| 2025-07-10 | 17.46x |
| 2025-07-09 | 17.76x |
| 2025-07-08 | 17.69x |
| 2025-07-07 | 17.95x |
| 2025-07-03 | 17.57x |
| 2025-07-02 | 17.24x |
| 2025-07-01 | 17.77x |
| 2025-06-30 | 17.89x |
| 2025-06-27 | 17.73x |
| 2025-06-26 | 17.63x |
| 2025-06-25 | 17.55x |
| 2025-06-24 | 17.61x |
| 2025-06-23 | 17.63x |
| 2025-06-20 | 17.61x |
| 2025-06-18 | 17.80x |
| 2025-06-17 | 17.69x |
| 2025-06-16 | 17.58x |
| 2025-06-13 | 17.78x |
| 2025-06-12 | 17.85x |
| 2025-06-11 | 17.53x |
| 2025-06-10 | 17.22x |
| 2025-06-09 | 17.30x |
| 2025-06-06 | 17.42x |
Showing the most recent 260 of 4,779 data points. The chart above shows the full history.
Related Metrics
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler